jounce.png
Jounce Therapeutics Announces Update on Vopratelimab Program
November 02, 2020 07:00 ET | Jounce Therapeutics, Inc.
- No further enrollment in EMERGE trial of vopratelimab in combination with ipilimumab based on interim analysis- - First patient dosed in SELECT trial of vopratelimab in combination with JTX-4014 in...
jounce.png
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
August 07, 2020 06:30 ET | Jounce Therapeutics, Inc.
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in...
jounce.png
Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
February 27, 2020 06:30 ET | Jounce Therapeutics, Inc.
- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 - - Ended 2019 with $170.4 million in...
jounce.png
Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies
February 06, 2020 08:00 ET | Jounce Therapeutics, Inc.
- Identification of a predictive biomarker – based on an 18 gene RNA signature and vopratelimab-specific threshold (TISvopra) – for the emergence of ICOS hi CD4 T cells that predicted clinical benefit...
jounce.png
Jounce Therapeutics to Present Safety and Preliminary Efficacy Data on JTX-4014 and a Trials in Progress Poster for the Vopratelimab EMERGE Study at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting
November 05, 2019 08:05 ET | Jounce Therapeutics, Inc.
- Recommended Phase 2 dose determined for future JTX-4014 trials - - Introducing the dosing and sequencing strategy for vopratelimab and ipilimumab in ongoing EMERGE Phase 2 trial - CAMBRIDGE,...
jounce.png
Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer
June 18, 2019 08:00 ET | Jounce Therapeutics, Inc.
- Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab - - Preliminary efficacy and relationship to biomarker data expected in 2020 - CAMBRIDGE,...
Kuebix.logo.highres.png
Kuebix Extends Load Matching Service with Emerge Marketplace
April 30, 2019 08:00 ET | Kuebix, LLC
MAYNARD, Mass. and SCOTTSDALE, Ariz., April 30, 2019 (GLOBE NEWSWIRE) -- Kuebix, creator of the industry’s fastest growing transportation management system (TMS), and Emerge, developer of the first...
ElmStreetTechnology-logo.jpg
Elm Street Technology Announces Acquisition of eMerge and Announces the Launch of 3sixtyfive, a Full-Service Creative and Digital Marketing Agency
October 17, 2018 08:00 ET | Elm Street Technology
Strategic Acquisition Will Provide Major Feature Enhancements to the Elevate Technology Platform and Provide Creative and Design Services to its Customers GREENSBORO, N.C. and NEW ORLEANS, Oct. 17,...